29 April 2016 - Novartis today announced that the CHMP of the EMA adopted a positive opinion for Afinitor (everolimus) for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease.

If approved by the European Commission, Afinitor would address an unmet need as there are currently few or no treatment options in Europe for patients with these diseases.

In February, the US FDA approved Afinitor for the treatment of adult patients with progressive, well-differentiated, nonfunctional NET of GI or lung origin that are unresectable, locally advanced or metastatic. Additional worldwide regulatory filings for this indication are underway.

For more details, go to: https://www.novartis.com/news/media-releases/novartis-drug-afinitorr-recommended-chmp-european-union-approval-treat-select-gi